Under Valued, page-2

Took a position today firsova at these prices. Believe this is a bargain play with a 5 mill market cap and cash at close to 4 mill. Biotechs have been getting hit along with the general market sentiment but they seem to bounce very hard when sentiment change. Have had some very nice bio winners on these bounces like PRR back after the GFC and this time have chosen VHL as my cheap spec play with multibagger potential on a turn around. Sitting at all time lows with a small market cap and with a decent product portfolio it is seriously undervalued compared to its peers at same or lesser advanced stage in product pipeline development. Recent acquisition from Yale university of the GGTI technology which shows to block important growth signals in cancer could turn out to be a company maker. Ready to move into phs1b/2 and with trials to be conducted at the Moffit Cancer center 1 of the leading US institutions and putting VHL in a position to potentially have multiple clinical trials under an FDA IND. Recent additions to the board of Dr Rob Crombie and Paul Hopper as well as leading expert advisory additions have strengthened the company moving forward. Not to forget the partnership with Transgene Sa France utilising the Co-X-Gene technology in 2 of its immunotherapeutic product of which 1 is moving into a phs3 study. Happy to have snapped up a decent amount at .5 today.